TY  - CONF

T1  - Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.

JO  - Journal of Clinical Oncology

PY  - 2018/05/20

AU  - Bullement A

AU  - D'Angelo SP

AU  - Amin A

AU  - Stapelkamp C

AU  - Willis A

AU  - Lilley C

AU  - Hatswell A

AU  - Bharmal M

ED  - 

DO  - DOI: 10.1200/jco.2018.36.15_suppl.e21620

PB  - American Society of Clinical Oncology (ASCO)

VL  - 36

IS  - 15_suppl

SP  - e21620

EP  - e21620

Y2  - 2025/03/11

ER  -